ADNOC Gas Targets Up to $4B Profit in 2026 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
CARLSBAD, Calif., Feb. 21, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that the Company plans to participate in two upcoming investor conferences.
- March 1, 2018, GenMark’s management is scheduled to participate in the BTIG Snowbird Healthcare Conference in Snowbird, UT. Due to the format of this event, no webcast is available.
- March 14, 2018 at 10:00am ET, GenMark’s management is scheduled to present at the Cowen & Co. 38th Annual Health Care Conference in Boston, MA. Interested parties can access the live and archived webcast at www.genmarkdx.com, under the investor relations section.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
